Long circulation and cytotoxicity of PEGylated gemcitabine and its potential for the treatment of pancreatic cancer

Biomaterials

Volumn 31, Issue 35, 2010, Pages 9340-9356

  Vandana, Mallaredy ^a   Sahoo, Sanjeeb K ^a  

^a INSTITUTE OF LIFE SCIENCES   (India)

Author keywords

Apoptosis; Bioavailability; Cytotoxicity; Gemcitabine; Pancreatic cancer; PEGylated gemcitabine

Indexed keywords

ANIMAL MODEL; ANTI-CANCER AGENTS; APOPTOSIS; APOPTOSIS-INDUCING ACTIVITY; BIOAVAILABILITY; CIRCULATION TIME; CLINICAL APPLICATION; DNA SYNTHESISS; DRUG-CONJUGATES; FOOD AND DRUG ADMINISTRATION; FRONTLINE; GEMCITABINE; INTRAVENOUS ADMINISTRATION; LOW MOLECULAR WEIGHT; PANCREATIC CANCERS; RP-HPLC; TUMOR UPTAKE; WATERSOLUBLE;

BIOCHEMISTRY; CELL CULTURE; CELL DEATH; CHEMICAL MODIFICATION; CYTOTOXICITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY;

DRUG PRODUCTS;

GEMCITABINE; MACROGOL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CHEMICAL MODIFICATION; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG CONJUGATION; DRUG FORMULATION; DRUG METABOLISM; DRUG RETENTION; FEMALE; INFRARED SPECTROSCOPY; INTRACELLULAR SIGNALING; MOUSE; NONHUMAN; PANCREAS CANCER; PANCREAS ISLET CELL CARCINOMA; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; APOPTOSIS; BLOTTING, WESTERN; CELL CYCLE; CELL LINE, TUMOR; DEOXYCYTIDINE; FEMALE; HUMANS; MEMBRANE POTENTIAL, MITOCHONDRIAL; MICE; MICE, INBRED BALB C; PANCREATIC NEOPLASMS;

AGOUTI PACA; ANIMALIA;

EID: 77957943569     PISSN: 01429612     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2010.08.010     Document Type: Article

References (72)

1. Damaraju V.L., Bouffard D.Y., Wong C.K., Clarke M.L., Mackey J.R., Leblond L., et al. Synergistic activity of troxacitabine (troxatyl) and gemcitabine in pancreatic cancer. BMC Cancer 2007, 7:121.
2. Li D., Xie K., Wolff R., Abbruzzese J.L. Pancreatic cancer. Lancet 2004, 363(9414):1049-1057.
3. Burris H.A., Moore M.J., Andersen J., Green M.R., Rothenberg M.L., Modiano M.R., et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997, 15(6):2403-2413.
4. Huang P., Chubb S., Hertel L.W., Grindey G.B., Plunkett W. Action of 2',2'-difluorodeoxycytidine on DNA synthesis. Cancer Res 1991, 51(22):6110-6117.
5. Mini E., Nobili S., Caciagli B., Landini I., Mazzei T. Cellular pharmacology of gemcitabine. Ann Oncol 2006, 17(Suppl. 5):v7-12.
6. Plunkett W., Huang P., Xu Y.Z., Heinemann V., Grunewald R., Gandhi V. Gemcitabine: metabolism, mechanisms of action, and self-potentiation. Semin Oncol 1995, 22(4 Suppl. 11):3-10.
7. Belt J.A., Marina N.M., Phelps D.A., Crawford C.R. Nucleoside transport in normal and neoplastic cells. Adv Enzyme Regul 1993, 33:235-252.
8. Garcia-Manteiga J., Molina-Arcas M., Casado F.J., Mazo A., Pastor-Anglada M. Nucleoside transporter profiles in human pancreatic cancer cells: role of hCNT1 in 2',2'-difluorodeoxycytidine- induced cytotoxicity. Clin Cancer Res 2003, 9(13):5000-5008.
9. Mackey J.R., Mani R.S., Selner M., Mowles D., Young J.D., Belt J.A., et al. Functional nucleoside transporters are required for gemcitabine influx and manifestation of toxicity in cancer cell lines. Cancer Res 1998, 58(19):4349-4357.
10. Eda H., Ura M., FO K., Tanaka Y., Miwa M., Ishitsuka H. The antiproliferative activity of DMDC is modulated by inhibition of cytidine deaminase. Cancer Res 1998, 58(6):1165-1169.
11. Immordino M.L., Brusa P., Rocco F., Arpicco S., Ceruti M., Cattel L. Preparation, characterization, cytotoxicity and pharmacokinetics of liposomes containing lipophilic gemcitabine prodrugs. J Control Release 2004, 100(3):331-346.
12. Robinson K., Lambiase L., Li J., Monteiro C., Schiff M. Fatal cholestatic liver failure associated with gemcitabine therapy. Dig Dis Sci 2003, 48(9):1804-1808.
13. Storniolo A.M., Allerheiligen S.R., Pearce H.L. Preclinical, pharmacologic, and phase I studies of gemcitabine. Semin Oncol 1997, 24(2 Suppl. 7). S7-2-S7-
14. Jiang P.H., Motoo Y., Sawabu N., Minamoto T. Effect of gemcitabine on the expression of apoptosis-related genes in human pancreatic cancer cells. World J Gastroenterol 2006, 12(10):1597-1602.
15. Duncan R. Drug-polymer conjugates: potential for improved chemotherapy. Anticancer Drugs 1992, 3(3):175-210.
16. Duncan R., Kopecek J. Soluble synthetic polymers as potential drug carriers. Adv Polym Sci 1984, 57:53-101.
17. Khandare J., Minko T. Polymer-drug conjugates: progress in polymeric prodrugs. Prog Polym Sci 2006, 31:359-397.
18. Parveen S., Sahoo S.K. Polymeric nanoparticles for cancer therapy. J Drug Target 2008, 16(2):108-123.
19. Duncan R., Seymour L.W., O'Hare K.B., Flanagan P.A., Wedge S., Hume I.C., et al. Preclinical evaluation of polymer-bound doxorubicin. J Control Release 1992, 19:331-346.
20. Harris J.M., Chess R.B. Effect of pegylation on pharmaceuticals. Nat Rev Drug Discov 2003, 2(3):214-221.
21. Morpurgo M., Veronese F.M. Conjugates of peptides and proteins to polyethylene glycols. Methods Mol Biol 2004, 283:45-70.
22. Veronese F.M., Pasut G. Protein, peptide and nonpeptide drug PEGylation for therapeutic application: a review. Expert Opin Ther Patents 2004, 14:859-894.
23. Choi H.K., Chun M.K., Lee S.H., Jang M.H., Kim H.D., Jung C.S., et al. In vitro and in vivo study of poly(ethylene glycol) conjugated ketoprofen to extend the duration of action. Int J Pharm 2007, 341(1-2):50-57.
24. Conover C.D., Zhao H., Longley C.B., Shum K.L., Greenwald R.B. Utility of poly(ethylene glycol) conjugation to create prodrugs of amphotericin B. Bioconjug Chem 2003, 14(3):661-666.
25. Min T., Ye H., Zhang P., Liu J., Zhang C., Shen W., et al. Water-soluble poly(ethylene glycol) prodrug of pemetrexed: synthesis, characterization, and preliminary cytotoxicity. J Appl Polym Sci 2009, 111:444-451.
26. Veronese F.M., Schiavon O., Pasut G., Mendichi R., Andersson L., Tsirk A., et al. PEG-doxorubicin conjugates: influence of polymer structure on drug release, in vitro cytotoxicity, biodistribution, and antitumor activity. Bioconjug Chem 2005, 16(4):775-784.
27. Maeda H., Wu J., Sawa T., Matsumura Y., Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release 2000, 65(1-2):271-284.
28. Matsumura Y., Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res 1986, 46(12 Pt 1):6387-6392.
29. Cavallaro G., Mariano L., Salmaso S., Caliceti P., Gaetano G. Folate-mediated targeting of polymeric conjugates of gemcitabine. Int J Pharm 2006, 307(2):258-269.
30. Pasut G., Canal F., Dalla Via L., Arpicco S., Veronese F.M., Schiavon O. Antitumoral activity of PEG-gemcitabine prodrugs targeted by folic acid. J Control Release 2008, 127(3):239-248.
31. Lammers T., Subr V., Peschke P., Kuhnlein R., Hennink W.E., Ulbrich K., et al. Image-guided and passively tumour-targeted polymeric nanomedicines for radiochemotherapy. Br J Cancer 2008, 99(6):900-910.
32. Lammers T., Subr V., Ulbrich K., Peschke P., Huber P.E., Hennink W.E., et al. Simultaneous delivery of doxorubicin and gemcitabine to tumors in vivo using prototypic polymeric drug carriers. Biomaterials 2009, 30(20):3466-3475.
33. Yoo H.S., Park T.G. Folate-receptor-targeted delivery of doxorubicin nano-aggregates stabilized by doxorubicin-PEG-folate conjugate. J Control Release 2004, 100(2):247-256.
34. Misra R., Acharya S., Dilnawaz F., Sahoo S.K. Sustained antibacterial activity of doxycycline-loaded poly(d, l-lactide-co-glycolide) and poly(epsilon-caprolactone) nanoparticles. Nanomedicine (Lond) 2009, 4(5):519-530.
35. Vandana M., Sahoo S.K. Optimization of physicochemical parameters influencing the fabrication of protein-loaded chitosan nanoparticles. Nanomedicine (Lond) 2009, 4(7):773-785.
36. Misra R., Sahoo S.K. Intracellular trafficking of nuclear localization signal conjugated nanoparticles for cancer therapy. Eur J Pharm Sci 2010, 39(1-3):152-163.
37. Jain T.K., Morales M.A., Sahoo S.K., Leslie-Pelecky D.L., Labhasetwar V. Iron oxide nanoparticles for sustained delivery of anticancer agents. Mol Pharmacol 2005, 2(3):194-205.
38. Dilnawaz F., Singh A., Mohanty C., Sahoo S.K. Dual drug loaded superparamagnetic iron oxide nanoparticles for targeted cancer therapy. Biomaterials 2010, 31(13):3694-3706.
39. Hafeli U.O., Riffle J.S., Harris-Shekhawat L., Carmichael-Baranauskas A., Mark F., Dailey J.P., et al. Cell uptake and in vitro toxicity of magnetic nanoparticles suitable for drug delivery. Mol Pharmacol 2009, 6(5):1417-1428.
40. Acharya S., Dilnawaz F., Sahoo S.K. Targeted epidermal growth factor receptor nanoparticle bioconjugates for breast cancer therapy. Biomaterials 2009, 30(29):5737-5750.
41. Dolbeare F., Gratzner H., Pallavicini M.G., Gray J.W. Flow cytometric measurement of total DNA content and incorporated bromodeoxyuridine. Proc Natl Acad Sci U S A 1983, 80(18):5573-5577.
42. Bortner C.D., Cidlowski J.A. Caspase independent/dependent regulation of K(+), cell shrinkage, and mitochondrial membrane potential during lymphocyte apoptosis. J Biol Chem 1999, 274(31):21953-21962.
43. Christgen M., Schniewind B., Jueschke A., Ungefroren H., Kalthoff H. Gemcitabine-mediated apoptosis is associated with increased CD95 surface expression but is not inhibited by DN-FADD in Colo357 pancreatic cancer cells. Cancer Lett 2005, 227(2):193-200.
44. Parsels L.A., Morgan M.A., Tanska D.M., Parsels J.D., Palmer B.D., Booth R.J., et al. Gemcitabine sensitization by checkpoint kinase 1 inhibition correlates with inhibition of a Rad51 DNA damage response in pancreatic cancer cells. Mol Cancer Ther 2009, 8(1):45-54.
45. Xiao Z., Xue J., Sowin T.J., Zhang H. Differential roles of checkpoint kinase 1, checkpoint kinase 2, and mitogen-activated protein kinase-activated protein kinase 2 in mediating DNA damage-induced cell cycle arrest: implications for cancer therapy. Mol Cancer Ther 2006, 5(8):1935-1943.
46. Greenwald R.B., Zhao H., Xia J., Martinez A. Poly(ethylene glycol) transport forms of vancomycin: a long-lived continuous release delivery system. J Med Chem 2003, 46(23):5021-5030.
47. Petrova S., Miloshev S., Mateva R., Iliev I. Synthesis of amphiphilic PEG-PCL-PEG triblock copolymers. J Univ Chem Tech Metall 2008, 43(2):199-204.
48. Sahoo S.K., Sawa T., Fang J., Tanaka S., Miyamoto Y., Akaike T., et al. Pegylated zinc protoporphyrin: a water-soluble heme oxygenase inhibitor with tumor-targeting capacity. Bioconjug Chem 2002, 13(5):1031-1038.
49. Schiavon O., Pasut G., Moro S., Orsolini P., Guiotto A., Veronese F.M. PEG-Ara-C conjugates for controlled release. Eur J Med Chem 2004, 39(2):123-133.
50. Aryal S., Hu C.M., Zhang L. Polymer-cisplatin conjugate nanoparticles for acid-responsive drug delivery. ACS Nano 2010, 4(1):251-258.
51. Bareford L.M., Swaan P.W. Endocytic mechanisms for targeted drug delivery. Adv Drug Deliv Rev 2007, 59(8):748-758.
52. Duncan R., Kopecek J., Lloyd J.B. Drug targeting to lysosomes. Biochem Soc Trans 1984, 12(6):913-915.
53. Giovannetti E., Leon L.G., Bertini S., Macchia M., Minutolo F., Funel N., et al. Study of apoptosis induction and deoxycytidine kinase/cytidine deaminase modulation in the synergistic interaction of a novel ceramide analog and gemcitabine in pancreatic cancer cells. Nucleosides Nucleotides Nucleic Acids 2010, 29(4-6):419-426.
54. Luhmann T., Rimann M., Bittermann A.G., Hall H. Cellular uptake and intracellular pathways of PLL-g-PEG-DNA nanoparticles. Bioconjug Chem 2008, 19(9):1907-1916.
55. Qanungo S., Das M., Haldar S., Basu A. Epigallocatechin-3-gallate induces mitochondrial membrane depolarization and caspase-dependent apoptosis in pancreatic cancer cells. Carcinogenesis 2005, 26(5):958-967.
56. Konishi A., Shimizu S., Hirota J., Takao T., Fan Y., Matsuoka Y., et al. Involvement of histone H1.2 in apoptosis induced by DNA double-strand breaks. Cell 2003, 114(6):673-688.
57. Kaufmann S.H., Desnoyers S., Ottaviano Y., Davidson N.E., Poirier G.G. Specific proteolytic cleavage of poly(ADP-ribose) polymerase: an early marker of chemotherapy-induced apoptosis. Cancer Res 1993, 53(17):3976-3985.
58. Carmichael J., Fink U., Russell R.C., Spittle M.F., Harris A.L., Spiessi G., et al. Phase II study of gemcitabine in patients with advanced pancreatic cancer. Br J Cancer 1996, 73(1):101-105.
59. Sahoo S.K., Parveen S., Panda J.J. The present and future of nanotechnology in human health care. Nanomedicine 2007, 3(1):20-31.
60. Parveen S., Sahoo S.K. Nanomedicine: clinical applications of polyethylene glycol conjugated proteins and drugs. Clin Pharmacokinet 2006, 45(10):965-988.
61. Couvreur P., Stella B., Reddy L.H., Hillaireau H., Dubernet C., Desmaele D., et al. Squalenoyl nanomedicines as potential therapeutics. Nano Lett 2006, 6(11):2544-2548.
62. Missirlis D., Kawamurab R., Tirelli N., Hubbella J.A. Doxorubicin encapsulation and diffusional release from stable, polymeric, hydrogel nanoparticles. Eur J Pharm Sci 2006, 29:120-129.
63. Babazadeh M. Design, synthesis and in vitro evaluation of vinyl ether type polymeric prodrugs of ibuprofen, ketoprofen and naproxen. Int J Pharm 2008, 356(1-2):167-173.
64. Takakura Y., Hashida M. Macromolecular carrier systems for targeted drug delivery: pharmacokinetic considerations on biodistribution. Pharm Res 1996, 13(6):820-831.
65. Lloyd J.B., Pratten M.K., Duncan R., Kooistra T., Cartlidge S.A. Substrate selection and processing in endocytosis. Biochem Soc Trans 1984, 12(6):977-978.
66. w 40000: synthesis, characterization, and structure-activity relationships in vitro and in vivo. Bioconjug Chem 2002, 13(4):773-785.
67. Cappella P., Tomasoni D., Faretta M., Lupi M., Montalenti F., Viale F., et al. Cell cycle effects of gemcitabine. Int J Cancer 2001, 93(3):401-408.
68. Morgan M.A., Parsels L.A., Parsels J.D., Mesiwala A.K., Maybaum J., Lawrence T.S. Role of checkpoint kinase 1 in preventing premature mitosis in response to gemcitabine. Cancer Res 2005, 65(15):6835-6842.
69. Koczor C.A., Shokolenko I.N., Boyd A.K., Balk S.P., Wilson G.L., Ledoux S.P. Mitochondrial DNA damage initiates a cell cycle arrest by a Chk2-associated mechanism in mammalian cells. J Biol Chem 2009, 284(52):36191-36201.
70. Green D.R., Reed J.C. Mitochondria and apoptosis. Science 1998, 281(5381):1309-1312.
71. Rogakou E.P., Pilch D.R., Orr A.H., Ivanova V.S., Bonner W.M. DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139. J Biol Chem 1998, 273(10):5858-5868.
72. Takahashi A., Ohnishi T. Does gammaH2AX foci formation depend on the presence of DNA double strand breaks?. Cancer Lett 2005, 229(2):171-179.